First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2027 revenue reaching $116M — +10.2% growth in a single year.
What Could Go Wrong
1Platform adoption risk - synthetic biology remains nascent with uncertain commercialization timelines; customers may develop in-house capabilities rather than outsourcing
2Technology obsolescence - rapid advances in AI-driven protein design, CRISPR tools, and competing automation platforms could erode competitive moat
3Regulatory uncertainty - evolving biosafety regulations and engineered organism approval pathways create commercialization barriers for customer products
4Large pharma in-house capabilities - companies like Amgen, Novo Nordisk building internal cell engineering platforms with superior resources
5Specialized competitors - Zymergen's failure demonstrates platform model risks; Twist Bioscience, Codexis, and Absci compete in specific verticals with focused approaches
6Customer concentration - loss of major programs or shift to insourcing by key customers would materially impact revenue
7Liquidity runway - with $400M+ annual cash burn and current ratio of 4.39, the company likely needs additional capital within 12-18 months absent significant improvement in cash flow
8Equity dilution risk - likely requires future equity raises at depressed valuations given market cap of only $500M, highly dilutive to existing shareholders